Novonesis (Novozymes) A/S risk profile
22 Normal where most of the sector sits
Measured 21 October 2026 from NSIS-B's filed statements. Recomputed nightly.
22 (Normal), driven by Competitive position at 23, over 3 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 21 | Normal | Stable | One-year price volatility — 27.9% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | 16 | Contained | Stable | Capital spending against operating cash — 0.34x |
| Leverage and coverage | Reads total_debt, cash_and_cash_equivalents, ebitda, interest_expense, total_current_assets, total_current_liabilities and a disclosed CET1 ratio, for a bank or insurer. No reading is stored for this company. | |||
| Competitive position | 23 | Normal | Stable | Operating-margin gap against peers — +5.3 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Basic Materials companies with a risk reading
Linde Plc. 28BHP Group Ltd 24Industria De Diseno Textil SA 20Southern Copper Corporation 13Rio Tinto Group 40Rio Tinto plc 37Newmont Corp 21L'Air Liquide S.A. 39Freeport-McMoRan Inc 35Agnico Eagle Mines Ltd 10Glencore plc 62Glencore PLC 62
Financials, valuation and price history for Novonesis (Novozymes) A/S